What does circulating tumor DNA (ctDNA) testing tell me about my Lymphoma

Understanding Circulating Tumor DNA (ctDNA) Testing for Lymphoma

Circulating tumor DNA (ctDNA) testing is an emerging blood-based test that detects tiny fragments of cancer DNA floating in your bloodstream. For lymphoma patients, this test can provide important information about how your cancer is responding to treatment and help predict whether your disease might return.

What ctDNA Testing Measures

When lymphoma cells die—either naturally or from treatment—they release DNA fragments into your blood. ctDNA testing detects these cancer-specific DNA fragments at very low levels. Think of it like finding a few grains of sand on a beach; the test is looking for that specific cancer "signature" in your blood.

For B-cell lymphomas (which includes many common types like diffuse large B-cell lymphoma and follicular lymphoma), ctDNA testing can identify the unique genetic patterns that make your cancer cells different from normal cells.

What This Means for Monitoring Your Lymphoma

According to the NCCN Guidelines for B-Cell Lymphomas (updated December 2024), ctDNA testing—specifically molecular residual disease (MRD) testing—is now included in treatment monitoring strategies. Here's what it can tell you:

After Treatment (End-of-Treatment Testing):

• Detects remaining cancer cells that might not show up on imaging scans yet
• Predicts relapse risk: Studies show ctDNA testing can identify patients at higher risk of their lymphoma returning before symptoms appear
• Earlier detection: ctDNA can detect recurrence approximately 200 days (about 6-7 months) earlier than PET/CT imaging in diffuse large B-cell lymphoma

During Surveillance:

• Helps guide how often you need imaging scans
• May influence decisions about additional treatment (called adjuvant therapy)
• Provides reassurance if results remain negative over time

How Accurate Is ctDNA Testing?

For lymphoma patients, ctDNA testing shows strong performance:

• Sensitivity: 90.62% (meaning it correctly identifies about 90% of patients who will later relapse)
• Specificity: 97.65% (meaning it correctly identifies about 98% of patients who won't relapse)
• Lead time advantage: Detects relapse approximately 200 days before PET/CT imaging

For comparison, traditional PET/CT imaging identified only 45% of patients who later relapsed, while ctDNA identified 90%.

Important Limitations and Considerations

Current Status:

• ctDNA testing for lymphoma is still relatively new in clinical practice
• The specific test (Foresight CLARITY Lymphoma) is currently available through research trials and limited clinical use, with broader clinical availability expected in 2026
• It requires a prior tumor tissue sample to establish your cancer's unique genetic signature (called "tumor-informed" testing)

What It Cannot Do:

• ctDNA testing is not a replacement for imaging scans or physical exams
• It doesn't diagnose lymphoma initially—it's used for monitoring after diagnosis
• A negative ctDNA result doesn't guarantee your lymphoma won't return; it means no detectable cancer DNA at that moment

Questions to Ask Your Oncology Team

If ctDNA testing interests you, consider asking your care team:

1. "Is ctDNA/MRD testing appropriate for my specific type of lymphoma and stage of treatment?"
2. "Would this test change how often I need imaging scans or affect my treatment plan?"
3. "Is this test available through your clinic, or would I need to participate in a clinical trial?"
4. "How would you use the results to guide my follow-up care?"
5. "What would a positive ctDNA result mean for my treatment options?"

The Bottom Line

ctDNA testing represents an exciting advancement in lymphoma monitoring that can detect cancer recurrence much earlier than traditional imaging. However, it's still being integrated into standard care. Your oncologist will determine whether this test is appropriate for your specific situation and how it fits into your overall treatment and surveillance plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.